Intercept's shares start coming back down to earth
- Intercept Pharmaceuticals' (ICPT) shares are -30% on what appears to be light volume after the stock skyrocketed 516% on Thursday and Friday following news that a trial for the company's (ICPT) beticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) was stopped early due to high efficacy.
- Intercept believes that an increase of "bad" cholesterol and decrease of "good" cholesterol in patients will probably be similar to results reported in 2009 regarding a trial of diabetic patients with nonalcoholic fatty liver disease.
- The efficacy, safety and tolerability profile of OCA was the basis for the drug's selection for treating NASH.
- There is also preclinical evidence that OCA may be "able to shunt excess lipids away from collecting in arteries and other organs, which could also be beneficial," Intercept says. (PR)
- Intercept CEO Mark Pruzanski says the company is open to working with a partner to bring OCA to market.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com
